CoChat

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

Wagner, Dimitrios L., Koehl, Ulrike, Chmielewski, Markus, Scheid, Christoph, Stripecke, Renata · 2022 · Frontiers in Immunology
Cited by 65

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered with gammaretroviral or lentiviral vectors (RVs/LVs) targeting B-cell lymphomas and leukemias have shown excellent clinical efficacy and no malignant transformation due to insertional mutagenesis to date. Large-scale production of RVs/LVs under good-manufacturing practices for CAR-T cell manufacturing has soared in recent years. However, manufacturing of RVs/LVs remains complex and costly, representing a logistical bottleneck for CAR-T cell production. Emerging gene-editing technologies are fostering a new paradigm in synthetic biology for the engineering and production of CAR-T cells. Firstly, the generation of the modular reagents utilized for gene editing with the CRISPR-Cas systems can be scaled-up with high precision under good manufacturing practices, are interchangeable and can be more sustainable in the long-run through the lower material costs. Secondly, gene editing exploits the precise insertion of CARs into defined genomic loci and allows combinatorial gene knock-ins and knock-outs with exciting and dynamic perspectives for T cell engineering to improve their therapeutic efficacy. Thirdly, allogeneic edited CAR-effector cells could eventually become available as “off-the-shelf” products. This review addresses important points to consider regarding the status quo, pending needs and perspectives for the forthright evolution from the viral towards gene editing developments for CAR-T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.865424

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 73

  1. Naldini, 2016, Lentiviral Vectors, Two Decades Later, Science, 353, 10.1126/science.aah6192 · DOI · Paper page
  2. Blaese, 1995, T Lymphocyte-Directed Gene Therapy for ADA- SCID: Initial Trial Results After 4 Years, Science, 270, 10.1126/science.270.5235.475 · DOI · Paper page
  3. Kraunus, 2004, Self-Inactivating Retroviral Vectors With Improved RNA Processing, Gene Ther, 11, 10.1038/sj.gt.3302309 · DOI
  4. Tucci, 2021, Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases, Mol Ther, 29, 489, 10.1016/j.ymthe.2020.11.020 · DOI
  5. Biasco, 2018, Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy, Mol Ther Methods Clin Dev, 8, 21, 10.1016/j.omtm.2017.10.002 · DOI
  6. Porter, 2011, Chimeric Antigen Receptor Therapy for B-Cell Malignancies, J Cancer, 2, 10.7150/jca.2.331 · DOI
  7. Locke, 2017, Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma, Mol Ther, 25, 10.1016/j.ymthe.2016.10.020 · DOI · Paper page
  8. Jain, 2021, Outcomes and Management of Patients With Mantle Cell Lymphoma After Progression on Brexucabtagene Autoleucel Therapy, Br J Haematol, 192, 10.1111/bjh.17197 · DOI
  9. Pearson, 2022, Paediatric Strategy Forum for Medicinal Product Development of Chimeric Antigen Receptor T-Cells in Children and Adolescents With Cancer: ACCELERATE in Collaboration With the European Medicines Agency With Participation of the Food and Drug Administration, Eur J Cancer, 160, 10.1016/j.ejca.2021.10.016 · DOI
  10. Monjezi, 2017, Enhanced CAR T-Cell Engineering Using non-Viral Sleeping Beauty Transposition From Minicircle Vectors, Leukemia, 31, 10.1038/leu.2016.180 · DOI · Paper page
  11. Magnani, 2020, Sleeping Beauty-Engineered CAR T Cells Achieve Antileukemic Activity Without Severe Toxicities, J Clin Invest, 130, 10.1172/JCI138473 · DOI · Paper page
  12. Rahrmann, 2019, Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-Cell Lymphoma, Mol Cancer Res, 17, 10.1158/1541-7786.MCR-18-0582 · DOI
  13. Barrett, 2013, Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice With Advanced Leukemia, Hum Gene Ther, 24, 10.1089/hum.2013.075 · DOI · Paper page
  14. Olbrich, 2017, Reconstructing the Immune System With Lentiviral Vectors, Virus Genes, 53, 10.1007/s11262-017-1495-2 · DOI
  15. Brandt, 2020, Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review, Front Immunol, 11, 10.3389/fimmu.2020.00326 · DOI · Paper page
  16. Zhao, 2015, Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells, Cancer Cell, 28, 10.1016/j.ccell.2015.09.004 · DOI · Paper page
  17. Zhang, 2021, Optimization of Metabolism to Improve Efficacy During CAR-T Cell Manufacturing, J Transl Med, 19, 499, 10.1186/s12967-021-03165-x · DOI
  18. Chmielewski, 2014, Of CARs and TRUCKs: Chimeric Antigen Receptor (CAR) T Cells Engineered With an Inducible Cytokine to Modulate the Tumor Stroma, Immunol Rev, 257, 83, 10.1111/imr.12125 · DOI · Paper page
  19. Castellarin, 2018, Driving Cars to the Clinic for Solid Tumors, Gene Ther, 25, 10.1038/s41434-018-0007-x · DOI
  20. Wilkie, 2012, Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling, J Clin Immunol, 32, 10.1007/s10875-012-9689-9 · DOI · Paper page
  21. Bielamowicz, 2018, Trivalent CAR T Cells Overcome Interpatient Antigenic Variability in Glioblastoma, Neuro Oncol, 20, 10.1093/neuonc/nox182 · DOI · Paper page
  22. Lanitis, 2013, Chimeric Antigen Receptor T Cells With Dissociated Signaling Domains Exhibit Focused Antitumor Activity With Reduced Potential for Toxicity In Vivo, Cancer Immunol Res, 1, 43, 10.1158/2326-6066.CIR-13-0008 · DOI · Paper page
  23. Chmielewski, 2017, CAR T Cells Releasing IL-18 Convert to T-Bet(high) FoxO1(low) Effectors That Exhibit Augmented Activity Against Advanced Solid Tumors, Cell Rep, 21, 10.1016/j.celrep.2017.11.063 · DOI · Paper page
  24. Song, 2016, In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice, Mol Cancer Ther, 15, 10.1158/1535-7163.MCT-16-0111 · doi:10.1158/1535-7163.mct-16-0111
  25. Ma, 2020, Interleukin-23 Engineering Improves CAR T Cell Function in Solid Tumors, Nat Biotechnol, 38, 10.1038/s41587-019-0398-2 · DOI · Paper page
  26. Chmielewski, 2015, TRUCKs: The Fourth Generation of CARs, Expert Opin Biol Ther, 15, 10.1517/14712598.2015.1046430 · DOI · Paper page
  27. Pincha, 2010, Lentiviral Vectors for Immunization: An Inflammatory Field, Expert Rev Vaccines, 9, 10.1586/erv.10.9 · DOI
  28. Bialek-Waldmann, 2021, Induced Dendritic Cells Co-Expressing GM-CSF/IFN-Alpha/Twt1 Priming T and B Cells and Automated Manufacturing to Boost GvL, Mol Ther Methods Clin Dev, 21, 10.1016/j.omtm.2021.04.004 · DOI
  29. Perry, 2021, Lentiviral Vector Bioprocessing, Viruses, 13, 1, 10.3390/v13020268 · DOI · Paper page
  30. Labbe, 2021, Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives, Viruses, 13, 1, 10.3390/v13081528 · DOI
  31. Kohl, 2018, CAR T Cells in Trials: Recent Achievements and Challenges That Remain in the Production of Modified T Cells for Clinical Applications, Hum Gene Ther, 29, 10.1089/hum.2017.254 · DOI · Paper page
  32. Buning, 2021, Gene Therapy "Made in Germany": A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy, Hum Gene Ther, 32, 10.1089/hum.2021.29178.hbu · DOI
  33. Vucinic, 2021, Production and Application of CAR T Cells: Current and Future Role of Europe, Front Med (Lausanne), 8, 10.3389/fmed.2021.713401 · DOI
  34. Aleksandrova, 2019, Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy(R) Platform, Transfus Med Hemother, 46, 47, 10.1159/000495772 · DOI · Paper page
  35. Jinek, 2012, A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity, Science, 337, 10.1126/science.1225829 · DOI · Paper page
  36. Wiebking, 2021, Genome Editing of Donor-Derived T-Cells to Generate Allogenic Chimeric Antigen Receptor-Modified T Cells: Optimizing Alphabeta T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation, Haematologica, 106, 10.3324/haematol.2019.233882 · DOI · Paper page
  37. Razeghian, 2021, A Deep Insight Into CRISPR/Cas9 Application in CAR-T Cell-Based Tumor Immunotherapies, Stem Cell Res Ther, 12, 428, 10.1186/s13287-021-02510-7 · DOI
  38. Ode, 2020, CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy, Cancers (Basel), 12, 1, 10.3390/cancers12061704 · DOI
  39. Kath, 2022, Pharmacological Interventions Enhance Virus-Free Generation of TRAC-Replaced CAR T Cells, Mol Ther Meth Clin Dev, 25, 10.1016/j.omtm.2022.03.018 · DOI · Paper page
  40. Muller, 2021, Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance, Front Immunol, 12, 10.3389/fimmu.2021.686439 · DOI
  41. Jing, 2021, Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells, Small Methods, 5, 10.1002/smtd.202100071 · DOI
  42. Nguyen, 2020, Polymer-Stabilized Cas9 Nanoparticles and Modified Repair Templates Increase Genome Editing Efficiency, Nat Biotechnol, 38, 10.1038/s41587-019-0325-6 · DOI · Paper page
  43. Gomes-Silva, 2017, CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-Cell Malignancies, Blood, 130, 10.1182/blood-2017-01-761320 · DOI · Paper page
  44. Blache, 2021, Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications, Front Immunol, 12, 10.3389/fimmu.2021.658314 · DOI · Paper page
  45. Lu, 2020, Safety and Feasibility of CRISPR-Edited T Cells in Patients With Refractory non-Small-Cell Lung Cancer, Nat Med, 26, 10.1038/s41591-020-0840-5 · DOI · Paper page
  46. Sheridan, 2022, Off-The-Shelf, Gene-Edited CAR-T Cells Forge Ahead, Despite Safety Scare, Nat Biotechnol, 40, 5, 10.1038/d41587-021-00027-1 · doi:10.1038/d41587-021-00027-1
  47. Morgan, 2020, Use of Cell and Genome Modification Technologies to Generate Improved "Off-The-Shelf" CAR T and CAR NK Cells, Front Immunol, 11, 10.3389/fimmu.2020.01965 · DOI
  48. Amini, 2021, CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients, Mol Ther, 29, 32, 10.1016/j.ymthe.2020.09.011 · DOI
  49. Bothmer, 2020, Detection and Modulation of DNA Translocations During Multi-Gene Genome Editing in T Cells, CRISPR J, 3, 10.1089/crispr.2019.0074 · DOI · Paper page
  50. Turchiano, 2021, Quantitative Evaluation of Chromosomal Rearrangements in Gene-Edited Human Stem Cells by CAST-Seq, Cell Stem Cell, 28, 1136, 10.1016/j.stem.2021.02.002 · DOI · Paper page
  51. Modlich, 2006, Cell-Culture Assays Reveal the Importance of Retroviral Vector Design for Insertional Genotoxicity, Blood, 108, 10.1182/blood-2005-08-024976 · DOI · Paper page
  52. Sachdeva, 2020, Author Correction: Repurposing Endogenous Immune Pathways to Tailor and Control Chimeric Antigen Receptor T Cell Functionality, Nat Commun, 11, 2357, 10.1038/s41467-020-16301-w · doi:10.1038/s41467-020-16301-w
  53. Wagner, 2021, Immunogenicity of CAR T Cells in Cancer Therapy, Nat Rev Clin Oncol, 18, 10.1038/s41571-021-00476-2 · DOI · Paper page
  54. Brentjens, 2007, Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts, Clin Cancer Res, 13, 10.1158/1078-0432.CCR-07-0674 · DOI · Paper page
  55. Tsukahara, 2013, CD19 Target-Engineered T-Cells Accumulate at Tumor Lesions in Human B-Cell Lymphoma Xenograft Mouse Models, Biochem Biophys Res Commun, 438, 10.1016/j.bbrc.2013.07.030 · DOI
  56. MacLeod, 2017, Integration of a CD19 CAR Into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells, Mol Ther, 25, 10.1016/j.ymthe.2017.02.005 · DOI · Paper page
  57. Stripecke, 2020, Innovations, Challenges, and Minimal Information for Standardization of Humanized Mice, EMBO Mol Med, 12, 10.15252/emmm.201708662 · DOI · Paper page
  58. Daniel, 2009, A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In Vitro, Cancer Res, 69, 10.1158/0008-5472.CAN-08-4210 · DOI · Paper page
  59. Takenaka, 2007, Polymorphism in Sirpa Modulates Engraftment of Human Hematopoietic Stem Cells, Nat Immunol, 8, 10.1038/ni1527 · DOI · Paper page
  60. Shultz, 2005, Human Lymphoid and Myeloid Cell Development in NOD/LtSz-Scid IL2R Gamma Null Mice Engrafted With Mobilized Human Hemopoietic Stem Cells, J Immunol, 174, 10.4049/jimmunol.174.10.6477 · DOI · Paper page
  61. du Manoir, 2014, Breast Tumor PDXs are Genetically Plastic and Correspond to a Subset of Aggressive Cancers Prone to Relapse, Mol Oncol, 8, 10.1016/j.molonc.2013.11.010 · DOI
  62. Zhu, 2015, Establishment and Characterization of Patient-Derived Tumor Xenograft Using Gastroscopic Biopsies in Gastric Cancer, Sci Rep, 5, 8542, 10.1038/srep08542 · DOI
  63. Hegde, 2016, Tandem CAR T Cells Targeting HER2 and IL13Ralpha2 Mitigate Tumor Antigen Escape, J Clin Invest, 126, 10.1172/JCI83416 · DOI · Paper page
  64. Rabilloud, 2021, Single-Cell Profiling Identifies Pre-Existing CD19-Negative Subclones in a B-ALL Patient With CD19-Negative Relapse After CAR-T Therapy, Nat Commun, 12, 865, 10.1038/s41467-021-21168-6 · DOI
  65. Teng, 2019, Chimeric Antigen Receptor-Modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-Derived Colon Carcinoma Xenograft Model, J Immunother, 42, 33, 10.1097/CJI.0000000000000251 · DOI · Paper page
  66. Labani-Motlagh, 2020, The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses, Front Immunol, 11, 10.3389/fimmu.2020.00940 · DOI · Paper page
  67. Shi, 2021, CAR T Cells Targeting CD99 as an Approach to Eradicate T-Cell Acute Lymphoblastic Leukemia Without Normal Blood Cells Toxicity, J Hematol Oncol, 14, 162, 10.1186/s13045-021-01178-z · DOI
  68. Cogels, 2021, Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research, Front Oncol, 11, 10.3389/fonc.2021.784947 · DOI
  69. Jin, 2019, Modeling Anti-CD19 CAR T Cell Therapy in Humanized Mice With Human Immunity and Autologous Leukemia, EBioMedicine, 39, 10.1016/j.ebiom.2018.12.013 · DOI
  70. Slabik, 2020, CAR-T Cells Targeting Epstein-Barr Virus Gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease, Mol Ther Oncolytics, 18, 10.1016/j.omto.2020.08.005 · DOI
  71. Leick, 2021, Clinical Perspective: Treatment of Aggressive B Cell Lymphomas With FDA-Approved CAR-T Cell Therapies, Mol Ther, 29, 10.1016/j.ymthe.2020.10.022 · DOI
  72. Graham, 2021, Gene-Edited Healthy Donor CAR T Cells Show Superior Anti-Tumour Activity Compared to CAR T Cells Derived From Patients With Lymphoma in an In Vivo Model of High-Grade Lymphoma, Leukemia, 35, 10.1038/s41375-021-01324-z · DOI
  73. Brown, 2021, Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis, Front Oncol, 11, 10.3389/fonc.2021.634445 · DOI

Cited by

See all 65

Metadata

Authors
Wagner, D. L., Koehl, U., Chmielewski, M., Scheid, C., & Stripecke, R.
Venue
Frontiers in Immunology
Published
2022-06-17
Volume
13
ISSN
1664-3224
Cited by
65
References
29
Funders
  • Deutsches Zentrum für Infektionsforschung
  • Deutsche Krebshilfe
  • Jackson Laboratory
  • Horizon 2020 Framework Programme

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing. https://app.cochat.ai/papers/10.3389/fimmu.2022.865424
The paper
Wagner, D. L., Koehl, U., Chmielewski, M., Scheid, C., & Stripecke, R. (2022). Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.865424

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.